Precision Medicine and Targeted Drug Delivery Signal a New Era for Kidney Care

Chronic kidney disease has quietly become one of the most formidable challenges in modern medicine. More than 10 percent of the world’s population lives with some degree of kidney impairment, and despite decades of research, many patients still progress relentlessly toward kidney failure, dialysis, or transplantation. A new collection of studies published in Frontiers in Nephrology argues that the field is now at an inflection point, where advances in immunology, molecular biology, and systems medicine are converging to replace the traditional one-size-fits-all approach with something far more precise: therapies and diagnostics tailored to the biology of each individual patient.

The editorial, authored by researchers at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS in Bergamo and the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico in Milan, frames the collection around a central tension in nephrology. Diabetes and hypertension account for most cases of chronic kidney disease, but a significant proportion of patients suffer from conditions that respond poorly to conventional treatment, including glomerular diseases, immune-mediated nephropathies, and rare genetic disorders. For these individuals, the editorial argues, the future lies in innovative strategies capable of slowing, stopping, or even reversing disease progression, rather than simply managing symptoms as they worsen.

One of the most striking themes to emerge from the collection is the growing role of immunomodulation in complex renal conditions. Kidney transplantation presents a particularly delicate balancing act: immunosuppressive drugs must prevent organ rejection while preserving the host’s ability to fight infection. Gregorini and colleagues describe a successful clinical experience with extracorporeal photopheresis in a highly complex kidney transplant recipient whose history included previous graft loss, BK-virus-associated nephropathy, profound alloimmunization, and thrombotic complications that ruled out standard therapeutic strategies. Extracorporeal photopheresis, a procedure in which a patient’s white blood cells are treated with a photosensitizing agent and ultraviolet light before being returned to the circulation, offered a personalized immunomodulatory approach capable of rebalancing immune responses without further compromising antiviral immunity.

What makes this case remarkable is not just the clinical outcome but the underlying philosophy it represents. Rather than broadly suppressing the immune system, the approach recalibrated it, modulating pathogenic responses with greater specificity and potentially fewer off-target effects. The editorial suggests this exemplifies how precision medicine in transplantation increasingly relies on individualized immunomodulation guided by the patient’s unique immunological profile, offering a promising option when conventional immunosuppressive adjustments are insufficient or contraindicated.

Beyond photopheresis, the collection points toward innovative cellular and immune-engineering approaches that could reshape transplant care. Mesenchymal stromal cell-based therapies have demonstrated promising immunomodulatory and tissue-reparative properties in organ transplantation and may contribute to the induction of graft tolerance while reducing the burden of long-term immunosuppression. At the same time, emerging technologies such as bi-specific autoantigen-T cell engagers seek to selectively eliminate autoreactive B cells by redirecting cytotoxic T cells toward pathogenic immune populations. Together, these approaches exemplify the ongoing shift toward precision immunotherapy, in which the immune system’s pathogenic components can be modulated with unprecedented specificity.

The refinement of pharmacological therapies in immune-mediated kidney diseases is advancing in parallel. Lupus nephritis, a condition historically associated with high morbidity and progression to kidney failure, has seen a significant step forward with the introduction of second-generation calcineurin inhibitors. Within the collection, Palmer and colleagues provide additional insight into the renal safety of voclosporin through a post hoc analysis of a small subgroup from the AURORA 1 trial. The authors demonstrated that voclosporin did not increase biomarkers of kidney injury or fibrosis despite its calcineurin-inhibitory mechanism, including among patients who experienced an early decline in estimated glomerular filtration rate. These findings are particularly relevant given longstanding concerns surrounding calcineurin inhibitor-associated nephrotoxicity, and they further support the favorable renal safety profile of this newer agent.

Improving outcomes in chronic kidney disease depends not only on therapeutic innovation but also on earlier and more accurate detection of kidney dysfunction. In this context, renewed attention to urine biochemistry offers a compelling and pragmatic approach. Maciel revisits the diagnostic value of urinary electrolytes, proposing a dynamic interpretation that moves beyond the traditional distinction between pre-renal and intrinsic acute kidney injury. By focusing on parameters such as urinary sodium concentration and fractional potassium excretion, this approach provides insight into renal microcirculatory stress and early functional impairment, offering a window into kidney physiology that serum-based measures cannot match.

The significance of this reframing becomes clear when considering the limitations of serum creatinine, which remains a delayed and often insensitive marker of kidney injury. Changes in urinary electrolyte patterns may precede creatinine elevation by several days, offering a valuable window for early intervention. Treating urine biochemistry as a real-time indicator of renal physiology supports a more dynamic, physiology-driven model of kidney monitoring, with potential applications extending beyond acute injury to the early detection of subclinical processes that contribute to chronic kidney disease progression.

Progression to end-stage kidney disease induces profound systemic consequences that become particularly evident in patients requiring maintenance hemodialysis. Beyond the well-described cardiorenal axis, Yu and colleagues review emerging evidence on the kidney-gut-brain axis, highlighting how gut dysbiosis, uremic toxins, chronic inflammation, and blood-brain barrier dysfunction contribute to cognitive impairment and neuropsychiatric complications in patients with advanced kidney disease. The review goes beyond providing a mechanistic framework, pointing to the potential of microbiome-derived biomarkers and targeted interventions to support more personalized approaches for this vulnerable population.

Taken together, the contributions in this collection highlight a rapidly evolving nephrology landscape in which a deeper understanding of disease mechanisms is increasingly translating into more precise and personalized approaches to diagnosis and treatment. From immune recalibration in transplantation and targeted immunotherapies in immune-mediated kidney diseases to innovative biomarkers and systems-based perspectives, these studies collectively emphasize the need to move beyond traditional disease classifications toward biologically informed strategies tailored to individual patients. The next phase of kidney medicine will require bridging the gap between scientific discovery and clinical implementation through robust validation of emerging therapies and biomarkers, integration of molecular and clinical information into decision-making pathways, and collaborative efforts across disciplines. The ultimate goal is to transform chronic kidney disease management from a predominantly reactive approach focused on slowing progression into a proactive model aimed at early intervention, disease modification, and preservation of kidney function for a broader and more diverse patient population.

Subject of Research: Editorial: Advancement in kidney care: targeted delivery and precision medicine approaches

Article Title: Editorial: Advancement in kidney care: targeted delivery and precision medicine approaches

Article References: Cerullo, D., Fiori, S., & Podestà, M. A. (2026). Editorial: Advancement in kidney care: targeted delivery and precision medicine approaches. Frontiers in Nephrology, 6, Article 1977844. https://doi.org/10.3389/fneph.2026.1977844

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1977844

Keywords: chronic kidney disease, precision medicine, immunotherapy, kidney transplantation, voclosporin, urinary biomarkers, gut-kidney-brain axis, nephrology, Editorial, Advancement, kidney, care